Algert Global LLC Erasca, Inc. Transaction History
Algert Global LLC
- $4.25 Billion
- Q4 2024
A detailed history of Algert Global LLC transactions in Erasca, Inc. stock. As of the latest transaction made, Algert Global LLC holds 51,364 shares of ERAS stock, worth $80,641. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51,364
Previous 35,960
42.84%
Holding current value
$80,641
Previous $98,000
31.63%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ERAS
# of Institutions
153Shares Held
221MCall Options Held
10.1KPut Options Held
79.3K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$30.4 Million2.85% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.7MShares$26.2 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$25.5 Million6.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$19.9 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA12.5MShares$19.6 Million4.12% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $192M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...